Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis

Clinical and Experimental Rheumatology

Volumn 32, Issue 6, 2014, Pages 891-897

  Ceribelli, Angela ^a,b   Fredi, Micaela ^c,d,e   Taraborelli, Mara ^c,d,e   Cavazzana, Ilaria ^c   Tincani, Angela ^c,d   Selmi, Carlo ^a,b   Chan, Jason Y F ^f   Chan, Edward K L ^g   Satoh, Minoru ^f,h   Franceschini, Franco ^c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Rheumatology and Clinical Immunology Unit Spedali Civili ^*  (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Autoantibodies; Dermatomyositis; Interstitial lung disease; MDA5; Polymyositis; Skin ulcers

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 ANTIBODY; METHOTREXATE; MJ ANTIBODY; MYCOPHENOLIC ACID; NXP 2 ANTIBODY; STEROID; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DEAD BOX PROTEIN; IFIH1 PROTEIN, HUMAN;

ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; CAUCASIAN; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; COHORT ANALYSIS; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPEAN; FEMALE; HUMAN; IMMUNOPRECIPITATION; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PAPULE; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SKIN DISEASE; WESTERN BLOTTING; AGED; BLOOD; HELA CELL LINE; IMMUNOLOGY; ITALY; K562 CELL LINE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE;

ADULT; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOTTING, WESTERN; DEAD-BOX RNA HELICASES; DERMATOMYOSITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HELA CELLS; HUMANS; IMMUNOPRECIPITATION; ITALY; K562 CELLS; MALE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 84925284516     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. MAMMEN AL: Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 2011; 7: 343-54.
2. TADA Y, SUEMATSU E, UEDA A et al.: Clinical factors to predict a poor prognosis and refractory disease in patients with polymyositis and dermatomyositis associated with interstitial lung disease. Clin Exp Rheumatol 2012; 30: 450.
3. TABORDA AL, AZEVEDO P, ISENBERG DA: Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long-term follow-up study. Clin Exp Rheumatol 2014; 32: 188-93.
4. SATOH M, CHAN EK, SOBEL ES et al.: Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol 2007; 3: 721-38.
5. SATOH M, CERIBELLI A, CHAN EK: Common pathways of autoimmune inflammatory myopathies and genetic neuromuscular disorders. Clin Rev Allergy Immunol 2012; 42: 16-25.
6. CASCIOLA-ROSEN L, MAMMEN AL: Myositis autoantibodies. Curr Opin Rheumatol 2012; 24: 602-8.
7. TARGOFF IN, MILLER FW, MEDSGER TA Jr, ODDIS CV: Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997; 9: 527-35.
8. ZONG M, LUNDBERG IE: Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 2011; 7: 297-306.
9. SATOH M, VAZQUEZ-DEL MERCADO M, CHAN EK: Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 2009; 19: 219-28.
10. SATOH M, CHAN JY, ROSS SJ et al.: Autoantibodies to transcription intermediary factor TIF1beta associated with dermatomyositis. Arthritis Res Ther 2012; 14: R79.
11. HORAI Y, ISOMOTO E, KOGA T et al.: Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Mod Rheumatol 2013; 23: 190-4.
12. SATO S, KUWANA M, FUJITA T, SUZUKI Y: Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol 2012; 22: 625-9.
13. SATO S, KUWANA M, FUJITA T, SUZUKI Y: Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 2013; 23: 496-502.
14. FIORENTINO D, CHUNG L, ZWERNER J, ROSEN A, CASCIOLA-ROSEN L: The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 25-34.
15. HALL JC, CASCIOLA-ROSEN L, SAMEDY LA et al.: Anti-MDA5-associated dermatomyositis: Expanding the clinical spectrum. Arthritis Care Res (Hoboken), 2013.
16. CHEN Z, CAO M, PLANA MN et al.: Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken) 2013; 65: 1316-24.
17. MURO Y, SUGIURA K, HOSHINO K, AKIYAMA M, TAMAKOSHI K: Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther 2011; 13: R214.
18. KANG EH, NAKASHIMA R, MIMORI T et al.: Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010; 11: 223.
19. BOHAN A, PETER JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
20. BOHAN A, PETER JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
21. SONTHEIMER RD: Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 2002; 20: 387-408.
22. SATOH M, CHAN EK, HO LA et al.: Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012; 64: 2319-27.
23. YAMASAKI Y, NARAIN S, HERNANDEZ L et al.: Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. Arthritis Res Ther 2006; 8: R111.
24. CERIBELLI A, FREDI M, TARABORELLI M et al.: Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 2012; 14: R97.
25. MURO Y, SUGIURA K, AKIYAMA M: Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clin Rheumatol 2013; 32: 395-8.
26. CHEN F, WANG D, SHU X, NAKASHIMA R, WANG G: Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int 2012; 32: 3909-15.
27. GONO T, KAWAGUCHI Y, SATOH T et al.: Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010; 49: 1713-9.
28. MURO Y, SUGIURA K, HOSHINO K, AKIYAMA M: Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford) 2012; 51: 800-4.
29. HOSHINO K, MURO Y, SUGIURA K et al.: Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010; 49: 1726-33.
30. YAMASAKI Y, YAMADA H, NOZAKI T et al.: Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006; 54: 2004-9.
31. PETRI MH, SATOH M, MARTIN-MARQUEZ BT et al.: Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther 2013; 15: R48.
32. SATOH M, CERIBELLI A, CHAN EK: Role of environmental factors in autoantibody production - importance of a detailed analysis in a small cohort. Arthritis Res Ther 2012; 14: 109.
33. SATO S, HIRAKATA M, KUWANA M et al.: Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571-6.
34. SATO S, HOSHINO K, SATOH T et al.: RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60: 2193-200.